Last Modified: March 2, 2003
Conference Dates: April 2, 2003
Conference Location: Boston, Massachusetts
Sponsoring Group: The Multiple Myeloma Research Foundation and Dana-Farber/Partners CancerCare
Conference Web Page URL: www.multiplemyeloma.org
Conference Objectives: To provide an opportunity for patients with myeloma and other members of the community to learn the latest treatment options for patients with myeloma.
Who Should Attend: Patients, family members, friends, others
Registration Information: For more information, please contact Sara Nichols, Program Coordinator, at (203)972-1250 and/or email@example.com
Conference Fees: Free
Continuing Education: No
Jan 30, 2015 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.
Jan 30, 2015
Dec 13, 2010